• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Newton Biocapital launches a new fund with initial capital commitments of EUR 50 million and target size of EUR 150 million

It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
The Walloon region is taking major steps towards becoming an important player in the business of plant-based proteins. In the next few months, two of the region’s public investment funds, Sogepa and SRIW, plan to establish a start-up company in this booming field. In the long term, the goal is to create an entire ecosystem around the use of plant proteins as meat replacements, benefiting the economy, health and sustainability of the whole area.
A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.
A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing a common anti-diabetic medication. The treatment has already been tested on several patients and has been a huge success with clinical trials now being initiated around the world.
The biotech Bioxodes is using a molecule derived from tick saliva to stop blood clots. The Walloon company is focused on preventing thrombosis during procedures involving medical devices. The current gold-standard anticoagulant can cause unwanted bleeding and side effects; could a molecule derived from ticks really be safer?
  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

It has been a year with ups and downs for Mithra – the Liège-based specialist in women’s health. The company experienced huge success with its pioneering contraceptive pill Estelle, which became available in regions all over the world. But the company also discontinued the research program of another product, PeriNesta, developed to battle symptoms arising during menopause. Overall the company is doing good work though, developing innovations in a field that has historically been neglected.
The Walloon region is taking major steps towards becoming an important player in the business of plant-based proteins. In the next few months, two of the region’s public investment funds, Sogepa and SRIW, plan to establish a start-up company in this booming field. In the long term, the goal is to create an entire ecosystem around the use of plant proteins as meat replacements, benefiting the economy, health and sustainability of the whole area.
A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.
A basic research breakthrough is improving patient lives, as researchers realized their rare genetic condition could be treated by repurposing a common anti-diabetic medication. The treatment has already been tested on several patients and has been a huge success with clinical trials now being initiated around the world.
The biotech Bioxodes is using a molecule derived from tick saliva to stop blood clots. The Walloon company is focused on preventing thrombosis during procedures involving medical devices. The current gold-standard anticoagulant can cause unwanted bleeding and side effects; could a molecule derived from ticks really be safer?